Latest News for: rigel

Edit

Rigel Provides Business Update and 2026 Outlook (Rigel Pharmaceuticals Inc)

Public Technologies 12 Jan 2026
January 12, 2026 Rigel Provides Business Update and 2026 Outlook ... Rigel anticipates full-year total revenue of approximately $275 to $290 million, including net product sales of $255 to $265 million, and positive net income for the full year.
Edit

January 2026 (Rigel Pharmaceuticals Inc)

Public Technologies 12 Jan 2026
) Corporate Presentation. January 12, 2026. Grow Commercial. Business. Maintain Financial. Discipline. In-Licensing / Business. Development. Advance Development. Pipeline. Grow Commercial. Business. Maintain Financial. Discipline ... 1 ... 2 ... 50 ... Rigel Pharmaceuticals Inc.
Edit

Rigel Provides Business Update and 2026 Outlook (Form 8-K) (Rigel Pharmaceuticals Inc)

Public Technologies 12 Jan 2026
) Rigel Provides Business Update and 2026 Outlook ... Rigel anticipates full-year total revenue of approximately $275 to $290 million, including net product sales of $255 to $265 million, and positive net income for the full year ... About Rigel.
Edit

Rigel Provides Business Update and 2026 Outlook

PR Newswire 12 Jan 2026
12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq ... Rigel expects to report fourth quarter of 2025 gross product sales of $84.5 million ... Rigel expects to provide complete fourth quarter and full year 2025 financial results in March 2026.
Edit

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PR Newswire 09 Jan 2026
9, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq. RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc ... Founded in 1996, Rigel is based in South San Francisco, California.
Edit

Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited

Hastings Tribune 08 Jan 2026
07, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading ...
Edit

SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030 - Rigel Pharmaceuticals Leads ...

Business Wire 08 Jan 2026
Report Findings & Highlights. Global SYK Inhibitor Market Growth 2020-2024.
Edit

Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio

Nasdaq Globe Newswire 07 Jan 2026
07, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading ...
Edit

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

PR Newswire 07 Jan 2026
7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc ... To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com ... SOURCE Rigel Pharmaceuticals, Inc.
Edit

SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook, 2030 - Rigel Pharmaceuticals Leads With Fostamatinib and Hutchmed's Sovleplenib Emerges as Late-Stage Breakthrough Candidate for ITP - ResearchAndMarkets.com

Pharmiweb 07 Jan 2026
Rigel Pharmaceuticals, with its marketed product fostamatinib, remains a key player, but other companies are also making strides in this field ... IACTA Pharmaceuticals Ignota Labs Rigel Pharmaceuticals.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Rigel Pharmaceuticals Inc)

Public Technologies 30 Dec 2025
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue ... 2 ... RIGEL PHARMACEUTICALS INC [RIGL] 5 ... RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900 3 ... RIGEL PHARMACEUTICALS, INC ... Rigel Pharmaceuticals Inc.
Edit

Opinion: How an accessory dwelling could turn into a 20-story tower in Berkeley

East Bay Times 17 Dec 2025
At first the plan for the property a block from UC Berkeley was modest. build a two-unit accessory dwelling behind a pair of small apartment buildings ... a 20-story tower with 169 apartments ... Letters ... Rigel Robinson is a former Berkeley City Councilmember.
Edit

How an accessory dwelling could turn into a 20-story tower

The Daily Journal - San Mateo 15 Dec 2025
At first the plan for the property a block from UC Berkeley was modest. build a two-unit accessory dwelling behind a pair of small apartment buildings ... .
Edit

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition (Form 8-K) (Rigel Pharmaceuticals Inc)

Public Technologies 10 Dec 2025
SOUTH SAN FRANCISCO, Calif., December 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc ... About Rigel. Rigel Pharmaceuticals, Inc ... Founded in 1996, Rigel is based in South San Francisco, California ... Rigel Pharmaceuticals Inc.
Edit

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with ...

Lebanon Express 08 Dec 2025
R289 continues to be generally well tolerated and at ...

Article Search

tools
×
×
×
×